KDM1A and acute myeloid leukemia: Together with the finding that pharmacological inhibition of LSD1 reduces GSE1, these data suggest the possibility of stratifying AML patients based on GSE1 expression levels to identify those who could benefit more from LSD1 inhibitor treatment.